Search

Immunocore Holdings PLC ADR

Geschlossen

37.06 0.98

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.4

Max

36.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

-14M

-786K

Verkäufe

9.3M

116M

EPS

-0.02

Gewinnspanne

-0.678

Angestellte

524

EBITDA

-13M

3.6M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+70.36% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

155M

1.8B

Vorheriger Eröffnungskurs

36.08

Vorheriger Schlusskurs

37.06

Immunocore Holdings PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower amid rising oil prices and geopolitical tensions, including new U.S. sanctions against Iran. No specific company news was identified.

21. Aug. 2026, 19:46 UTC

News

IMCR gains as JPMorgan reinstates coverage with Overweight rating.

20. Aug. 2026, 20:02 UTC

Immunocore Holdings PLC shares are lower today, reflecting declines in the Biotechnology sub-sector. The stock has shown notable volatility during the session.

19. Aug. 2026, 22:51 UTC

Immunocore Holdings PLC shares are higher in after-market hours, continuing an upward trend. No specific news was identified to explain the movement.

18. Aug. 2026, 20:01 UTC

Immunocore Holdings PLC is rising amid biotechnology sector strength, despite pulling back from an earlier session high. No specific company news was identified.

17. Aug. 2026, 19:23 UTC

News

Immunocore Holdings PLC shares are higher today following HC Wainwright's improved Q3 2026 earnings estimates, raising loss per share projections to -$0.08 from -$0.25.

14. Aug. 2026, 22:16 UTC

Immunocore Holdings PLC shares are lower in after-market trading. Broader market sentiment is impacted by declining retail sales and consumer confidence.

11. Aug. 2026, 20:01 UTC

Immunocore Holdings PLC is rising as biotechnology sector strength supports shares, though the stock has pulled back from an earlier session high.

10. Aug. 2026, 19:16 UTC

News

Immunocore Holdings PLC reports second-quarter revenue of $115.93 million, with shares lower amid broader market trends and declining U.S. stock futures.

7. Aug. 2026, 20:04 UTC

News

Immunocore Holdings reported a wider Q2 loss of 2 cents per share and $115.9 million in revenue, with shares trading lower since Thursday's close.

6. Aug. 2026, 19:52 UTC

News

Immunocore Holdings PLC reported Q2 earnings of -$0.02 per share and revenue of $115.93 million, exceeding expectations. Shares are trading higher during Thursday's session.

5. Aug. 2026, 20:02 UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

4. Aug. 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3. Aug. 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31. Juli 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28. Juli 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27. Juli 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24. Juli 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22. Juli 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21. Juli 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20. Juli 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Peer-Vergleich

Kursveränderung

Immunocore Holdings PLC ADR Prognose

Kursziel

By TipRanks

70.36% Vorteil

12-Monats-Prognose

Durchschnitt 62.83 USD  70.36%

Hoch 100 USD

Tief 35 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Immunocore Holdings PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

4

Buy

2

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat